Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant human neuregulin-1 for subcutaneous administration in chronic systolic heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• recombinant human neuregulin-1β (neuregulin-1β)

Snippet

Sponsor: Zensun Sci. & Tech. Co., Ltd. | Conditions: Chronic Heart Failure | Phase 3 | Status: TERMINATED